Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 1, 2016, Pages 213-221

  Kapil, Shweta ^a   Duseja, Ajay ^a   Sharma, Bal Krishan ^a   Singla, Bhupesh ^a   Chakraborti, Anuradha ^a   Das, Ashim ^a   Ray, Pallab ^a   Dhiman, Radha K ^a   Chawla, Yogesh ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

NAFLD; NASH; Non alcoholic steatohepatitis; PAMPS; SIBO; TLR

Indexed keywords

ADIPONECTIN; CD14 ANTIGEN; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MESSENGER RNA; PROTEIN MD 2; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TLR4 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BACTERIAL OVERGROWTH; CONTROLLED STUDY; DISEASE SEVERITY; DUODENUM FLUID; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; BLOOD; DUODENUM; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; DUODENUM; ENDOTOXINS; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956905459     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13058     Document Type: Article

References (28)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-609.
2. Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010; 52: 2248-9.
3. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-87.
4. Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin. Liver Dis. 2014; 18: 59-71.
5. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48: 206-11.
6. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7
7. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin. Exp. Res. 2005 Nov; 29(11 Suppl):140S-145S.
8. Duseja A, Das A, Das R et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig. Dis. Sci. 2007; 52: 2368-74.
9. Expert panel on detection, evaluation and treatment of high cholesterol in adults executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adults treatment panel III). JAMA 2001; 285: 2486-2497.
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
11. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-59.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-DeltaDelta C (T) Method. Methods. 2001; 25: 402-8.
13. Mozer-Lisewska I, Sluzewski W, Kaczmarek M, Jenek R, Szczepanski M, Figlerowicz M et al. Tissue localization of toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus. Scand. J. Immunol. 2005; 62: 407-12.
14. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
15. Keighley MR, Burdon DW. Identification of bacteria in the bile by duodenal aspiration. World J. Surg. 1978; 2: 255-9.
16. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology 1989; 36: 349-51.
17. Rana D, Duseja A, Dhiman RK, Chawla Y, Arora SK. Maturation defective myeloid dendritic cells in nonalcoholic fatty liver disease patients release inflammatory cytokines in response to endotoxin. Hepatol. Int. 2013; 7: 562-569
18. Wells CL, Jechorek RP, Gillingham KJ. Relative contributions of host and microbial factors in bacterial translocation. Arch. Surg. 1991; 126: 247-52.
19. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009; 58: 704-20.
20. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-9.
21. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011; 56: 1524-34.
22. Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2013.
23. Da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. Transfer from CD14 to TLR4 and MD-2. J. Biol. Chem. 2001; 276: 21129-35
24. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-72.
25. Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R et al. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J. Hepatol. 2013; 5: 189-95.
26. Calvano JE, Agnese DM, Um JY, Goshima M, Singhal R, Coyle SM et al. Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome positive patients with and without infection: relationship to tolerance. Shock. 2003; 20: 415-9.
27. Singh R, Bullard J, Kalra M, Assefa S, Kaul AK, Vonfeldt K et al. Status of bacterial colonization, toll-like receptor expression and nuclear factor-kappa B activation in normal and diseased human livers. Clin. Immunol. 2011; 138: 41-9.
28. Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am. J. Physiol. Gastrointest Liver Physiol. 2001; 281: G382-92.